Skip to main content
EBGLYSS 250 mg/2mL injection, solution by Eli Lilly and Company
EBGLYSS, 250 mg/2mL, injection, solution Drug class: Interleukin-13 Antagonist. Available on prescription only. Listed by Eli Lilly and Company.
Prescription only

EBGLYSS

lebrikizumab-lbkz

Listed by Eli Lilly and Company

Strength
250 mg/2mL
Form
Injection, Solution
Route
Subcutaneous
Class
Interleukin-13 Antagonist

What it contains

  • Lebrikizumab 250 mg/2mL

FDA record

Dosage form Injection, Solution
Route Subcutaneous
Drug class Interleukin-13 Antagonist
Approval route BLA — biologic licence
NDC code 0002-7797
FDA application BLA761306
RxNorm concept 2693784
Package sizes listed 2
Marketed since September 2024

Other products containing Lebrikizumab

See all

Same active ingredient, different manufacturer, strength or form. Products matching on both ingredient and strength are usually interchangeable — but confirm before switching, especially with modified-release forms.

EBGLYSS

lebrikizumab-lbkz

Strength
250 mg/2mL
Form
Injection, Solution
Class
Interleukin-13 Antagonist
Rx only

Eli Lilly and Company

Not stocked by us — reference only

Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.